L-dopa and carbidopa can effectively treat neuroleptic malignant syndrome-like states induced by the withdrawal of antiparkinsonian drugs, suggesting dopaminergic hypoactivity as a shared underlying mechanism.
Answers are grounded in this paper and cite their sources.
May support dopaminergic trial in refractory withdrawal states; leaves open confirmation in controlled studies.
A 63-year-old woman with diagnosis of Parkinson's disease developed an unusual symptom complex which consisted of extrapyramidal symptoms, disturbances of consciousness, diaphoresis, fever, and increased serum creatine phosphokinase following the discontinuation of large doses of combined antiparkinsonian drugs. After the patient's condition did not improve with the first 14 days of treatment consisting of intravenous fluids and antibiotics, a trial administration of L-dopa and carbidopa brought about definite clinical improvement. The symptoms strongly resembled neuroleptic malignant syndrome which is often a serious complication of antipsychotic drugs. The symptoms and the treatment of the present case suggest that dopaminergic hypoactivity in the brain may be an important factor in antiparkinsonian drug withdrawal syndrome and that similar neurochemical mechanisms may exist in neuroleptic malignant syndrome.
No takes yet. Share an insight, caveat, or question.
Toru et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: